FY23Q1
- Guidance: 30% consolidated revenue growth, 32-33% EBITDA margin. Will be back to 36% EBITDA margin by FY25
- Zomelis brand has crossed 8.3 cr. monthly sales (annual run-rate of 100 cr.). This should be the 4th 100 cr. brand by end of FY23
- Oaknet: Quarterly run rate of 55 cr. sales and 10 cr. EBITDA
- Cardio market has started reviving in June-July (average growth has increased to 13% vs 2% in the past twelve month)
- Aprica: profitability will be maintained ~20%
- In order to get to 14-15% organic growth trajectory, IPM growth has to come back to 8-10%
- Expect 200 bps pressure on gross margin due to newer launches
- Expect to deliver 20 cr.+ annual sales of insulin with EBITDA loss of 15 cr. Will launch insulin Glargine in Q3FY23 (in-licensed from Biocon). One-time payment and then sourcing arrangement (no recurring royalties)
- Gujarat facility will commence in Q4FY23 – capex incurred was 34 cr. (100 cr. incurred till date). Total expected capex ~ 170-180 cr.
- EBITDA margins will be impacted: (1) EBITDA losses due to insulin launch, (2) a lot of new product launches in cardiology in Q2 and Q3, (3) Oaknet margins
- Have not had new launches in CNS, but this segment is growing at 20-25%
- Trade generics: Had 8 cr. EBITDA loss in FY22 and will move to breakeven in FY23
Disclosure: Same as before
| Subscribe To Our Free Newsletter |
